These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27428375)

  • 41. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
    Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
    Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    Vos JR; Oosterwijk JC; Aalfs CM; Rookus MA; Adank MA; van der Hout AH; van Asperen CJ; Gómez Garcia EB; Mensenkamp AR; Jager A; Ausems MG; Mourits MJ; de Bock GH;
    Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1251-8. PubMed ID: 27277847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
    Couch FJ; Gaudet MM; Antoniou AC; Ramus SJ; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; Wang X; Kirchhoff T; McGuffog L; Barrowdale D; Lee A; Healey S; Sinilnikova OM; Andrulis IL; ; Ozcelik H; Mulligan AM; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Caligo MA; von Wachenfeldt A; Barbany-Bustinza G; Loman N; Soller M; Ehrencrona H; Karlsson P; ; Nathanson KL; Rebbeck TR; Domchek SM; Jakubowska A; Lubinski J; Jaworska K; Durda K; Zlowocka E; Huzarski T; Byrski T; Gronwald J; Cybulski C; Górski B; Osorio A; Durán M; Tejada MI; Benitez J; Hamann U; Hogervorst FB; ; van Os TA; van Leeuwen FE; Meijers-Heijboer HE; Wijnen J; Blok MJ; Kets M; Hooning MJ; Oldenburg RA; Ausems MG; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Jacobs C; Eeles RA; Adlard J; Davidson R; Eccles DM; Cole T; Cook J; Paterson J; Brewer C; Douglas F; Hodgson SV; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Side LE; ; Bove B; Godwin AK; Stoppa-Lyonnet D; ; Fassy-Colcombet M; Castera L; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Bressac-de Paillerets B; Caron O; Pujol P; Coupier I; Delnatte C; Akloul L; Lynch HT; Snyder CL; Buys SS; Daly MB; Terry M; Chung WK; John EM; Miron A; Southey MC; Hopper JL; Goldgar DE; Singer CF; Rappaport C; Tea MK; Fink-Retter A; Hansen TV; Nielsen FC; Arason A; Vijai J; Shah S; Sarrel K; Robson ME; Piedmonte M; Phillips K; Basil J; Rubinstein WS; Boggess J; Wakeley K; Ewart-Toland A; Montagna M; Agata S; Imyanitov EN; Isaacs C; Janavicius R; Lazaro C; Blanco I; Feliubadalo L; Brunet J; Gayther SA; Pharoah PP; Odunsi KO; Karlan BY; Walsh CS; Olah E; Teo SH; Ganz PA; Beattie MS; van Rensburg EJ; Dorfling CM; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Heinritz W; Caldes T; de la Hoya M; Muranen TA; Nevanlinna H; Tischkowitz MD; Spurdle AB; Neuhausen SL; Ding YC; Lindor NM; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Bernard L; Viel A; Giannini G; Varesco L; Radice P; Greene MH; Mai PL; Easton DF; Chenevix-Trench G; ; Offit K; Simard J;
    Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):645-57. PubMed ID: 22351618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Yang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Zhang J; Xie Y
    Breast Cancer Res Treat; 2019 Apr; 174(3):639-647. PubMed ID: 30607632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
    Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
    Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
    Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    Nilsson MP; Nilsson ED; Borg Å; Brandberg Y; Silfverberg B; Loman N
    Breast Cancer Res Treat; 2019 Jan; 173(2):313-318. PubMed ID: 30311024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing.
    Liang Y; Yang X; Li H; Zhu A; Guo Z; Li M
    Med Sci Monit; 2018 Apr; 24():2465-2475. PubMed ID: 29681614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
    Hall MJ; Reid JE; Wenstrup RJ
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1579-85. PubMed ID: 21149333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
    Basu NN; Ingham S; Hodson J; Lalloo F; Bulman M; Howell A; Evans DG
    Fam Cancer; 2015 Dec; 14(4):531-8. PubMed ID: 26239694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2.
    Park B; Dowty JG; Ahn C; Win AK; Kim SW; Lee MH; Lee JW; Kang E; Hopper JL; Park SK
    Breast Cancer Res Treat; 2015 Aug; 152(3):659-65. PubMed ID: 26195121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
    Cao WM; Gao Y; Yang HJ; Xie SN; Ding XW; Pan ZW; Ye WW; Wang XJ
    BMC Cancer; 2016 Feb; 16():64. PubMed ID: 26852015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
    Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.
    McCarthy AM; Bristol M; Fredricks T; Wilkins L; Roelfsema I; Liao K; Shea JA; Groeneveld P; Domchek SM; Armstrong K
    Cancer; 2013 Oct; 119(20):3596-603. PubMed ID: 23861169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
    Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.